ALGS on XNAS, Health Care, Aligos Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 85% in 12 months to $1.22 while cash of $31.1M sits above a $7.8M market cap.
BadShort interest at 698K shares, 2.4 times a year earlier
BadNet loss of $66.3M against $5.8M revenue, up 122%
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 4 Mar 2027 (an estimate: a year ago it reported on 5 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.8M, net loss $21.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $82.2M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$2.8M
-$21.9M
30 Jun 2026
$0
-$1.5M
31 Mar 2026
$2.8M
-$23.0M
31 Dec 2025
$169K
-$19.9M
30 Sep 2025
$741K
-$31.5M
30 Jun 2025
$965K
-$15.9M
31 Mar 2025
$311K
$43.1M
31 Dec 2024
$606K
-$82.2M
30 Sep 2024
$1.2M
-$19.3M
30 Jun 2024
$1.1M
$5.1M
31 Mar 2024
$694K
-$34.9M
31 Dec 2023
$672K
-$27.9M
30 Sep 2023
$1.1M
-$18.0M
30 Jun 2023
$4.3M
-$18.8M
31 Mar 2023
$140K
-$23.0M
31 Dec 2022
$0
-$21.9M
30 Sep 2022
$0
-$18.6M
30 Jun 2022
$0
-$19.9M
31 Mar 2022
–
-$35.6M
31 Dec 2021
–
-$37.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$5.8M
$2.6M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+122%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$66.3M
-$86.5M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-159%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$31.1M
$99.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$31.1M (net cash)
-$99.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.3
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.67
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+16%
36 13F filers vs 31
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
677K shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
20.8
677K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-4.3%
707K shares sold short in the report before, 677K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
62%
62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 46%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$220K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
10
10 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
10×
10 articles in the last 7 days; its usual week has 1.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 698K, 2.4× a year earlier
Price $1.22 on 20 Nov 2026, -85% over 12 months (12-month range $1.22 to $13.29)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months (none in the 12 months before).Revenue per quarter. Revenue $2.8M in the latest quarter, +282% on a year earlier.Capital spending per quarter. Capital spending $7K in the latest quarter, -99% on a year earlier.Institutional holders (13F filers). 36 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.Lobbying spend. Lobbying spend: $220K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 30 Jun 2022: $0; public on 4 Aug 2023
Quarter ended 30 Sep 2022: $0; public on 3 Nov 2023
Quarter ended 31 Dec 2022: $0; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $140K; public on 5 May 2023
Quarter ended 30 Jun 2023: $4.3M; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $1.1M; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $672K; public on 13 Mar 2024
Quarter ended 31 Mar 2024: $694K, +396% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.1M, -75% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $1.2M, +15% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $606K, -9.8% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $311K, -55% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $965K, -9.0% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $741K, -41% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $169K, -72% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $2.8M, +810% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $2.8M, +282% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $336K, +451% on a year earlier; public on 11 Mar 2022
Quarter ended 31 Mar 2022: $515K, +68% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $334K, +120% on a year earlier; public on 5 Aug 2022
Quarter ended 31 Dec 2022: $91K, -73% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $7K, -99% on a year earlier; public on 5 May 2023
Institutional holders (13F filers)
31 Dec 2021 report: 67; public on 14 Feb 2022
31 Mar 2022 report: 74; public on 16 May 2022
30 Jun 2022 report: 60; public on 15 Aug 2022
30 Sep 2022 report: 50; public on 14 Nov 2022
31 Dec 2022 report: 38; public on 14 Feb 2023
31 Mar 2023 report: 43; public on 15 May 2023
30 Jun 2023 report: 40; public on 14 Aug 2023
30 Sep 2023 report: 34; public on 14 Nov 2023
31 Dec 2023 report: 40; public on 14 Feb 2024
31 Mar 2024 report: 49; public on 15 May 2024
30 Jun 2024 report: 47; public on 14 Aug 2024
30 Sep 2024 report: 27; public on 14 Nov 2024
31 Dec 2024 report: 34; public on 14 Feb 2025
31 Mar 2025 report: 35; public on 15 May 2025
30 Jun 2025 report: 35; public on 14 Aug 2025
30 Sep 2025 report: 32; public on 14 Nov 2025
31 Dec 2025 report: 40; public on 17 Feb 2026
31 Mar 2026 report: 34; public on 15 May 2026
30 Jun 2026 report: 31; public on 14 Aug 2026
30 Sep 2026 report: 36; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2023: $8.5M published
Month from 1 Apr 2024: $1.3M published
Month from 1 Jul 2024: $0 published
Month from 1 Apr 2025: $1.5M published
Month from 1 Jun 2025: $0 published
Lobbying spend
Quarter from 1 Apr 2023: $110K published
Quarter from 1 Jul 2023: $110K published
Quarter from 1 Jan 2026: $80K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $60K published
What is unusual now
Made public in the last 90 days: it had 698K shares sold short in the 15 Sep 2026 report, 2.4× the same report last year; it also had 709K shares sold short in the 30 Sep 2026 report, 2.6× the same report last year. 5 sharp changes in all.
Short interest spike: had 607K shares sold short in the 31 Jul 2026 report, 1.7× the same report last year Public on 12 Aug 2026.
Reported lobbying spend: $60K in Q2 2026, $80K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
24 Jan 2023
New
Wilmer Cutler Pickering Hale And Dorr LLPfor Aligos Therapeutics, Inc.
Changes and notable records, by the date each became public
27 Oct 2026Short interest and volume change
had 707K shares sold short in the 15 Oct 2026 report, 3.0× the same report last year.
Same report last year: 235K; its normal report is 301K.
See the evidence
This period
707K (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
301K
Typical spread (median absolute deviation)
74K
How far from its usual level
+3.7
Same report last year
235K
History used
2,176 days
the 15 Oct 2026 report24 earlier reportsnormal: 301K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 709K shares sold short in the 30 Sep 2026 report, 2.6× the same report last year.
Same report last year: 273K; its normal report is 294K.
See the evidence
This period
709K (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
294K
Typical spread (median absolute deviation)
64K
How far from its usual level
+4.4
Same report last year
273K
History used
2,161 days
the 30 Sep 2026 report24 earlier reportsnormal: 294K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 698K shares sold short in the 15 Sep 2026 report, 2.4× the same report last year.
Same report last year: 292K; its normal report is 293K.
See the evidence
This period
698K (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
59K
How far from its usual level
+4.6
Same report last year
292K
History used
2,146 days
the 15 Sep 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 649K shares sold short in the 31 Aug 2026 report, 2.1× the same report last year.
Same report last year: 312K; its normal report is 293K.
See the evidence
This period
649K (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
55K
How far from its usual level
+4.3
Same report last year
312K
History used
2,131 days
the 31 Aug 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 568K shares sold short in the 14 Aug 2026 report, 1.9× the same report last year.
Same report last year: 303K; its normal report is 293K.
See the evidence
This period
568K (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
44K
How far from its usual level
+4.3
Same report last year
303K
History used
2,114 days
the 14 Aug 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 607K shares sold short in the 31 Jul 2026 report, 1.7× the same report last year.
Same report last year: 362K; its normal report is 293K.
See the evidence
This period
607K (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
44K
How far from its usual level
+4.9
Same report last year
362K
History used
2,100 days
the 31 Jul 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 577K shares sold short in the 29 May 2026 report, 1.0× the same report last year.
Same report last year: 553K; its normal report is 293K.
See the evidence
This period
577K (the 29 May 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
44K
How far from its usual level
+4.4
Same report last year
553K
History used
2,037 days
the 29 May 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 535K shares sold short in the 15 May 2026 report, 16% below the same report last year.
Same report last year: 640K; its normal report is 293K.
See the evidence
This period
535K (the 15 May 2026 report)
Normal report (median of 24 earlier)
293K
Typical spread (median absolute deviation)
44K
How far from its usual level
+3.8
Same report last year
640K
History used
2,023 days
the 15 May 2026 report24 earlier reportsnormal: 293K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 28 Jun 2024 report, 2.6× the same report last year.
Same report last year: 818K; its normal report is 771K.
See the evidence
This period
2.2M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
771K
Typical spread (median absolute deviation)
68K
How far from its usual level
+13.6
Same report last year
818K
History used
1,337 days
the 28 Jun 2024 report24 earlier reportsnormal: 771K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 14 Jun 2024 report, 2.4× the same report last year.
Same report last year: 786K; its normal report is 771K.
See the evidence
This period
1.9M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
771K
Typical spread (median absolute deviation)
57K
How far from its usual level
+12.8
Same report last year
786K
History used
1,323 days
the 14 Jun 2024 report24 earlier reportsnormal: 771K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.9M shares sold short in the 31 May 2024 report, 2.0× the same report last year.
Same report last year: 917K; its normal report is 771K.
See the evidence
This period
1.9M (the 31 May 2024 report)
Normal report (median of 24 earlier)
771K
Typical spread (median absolute deviation)
57K
How far from its usual level
+12.8
Same report last year
917K
History used
1,309 days
the 31 May 2024 report24 earlier reportsnormal: 771K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 15 May 2024 report, 1.5× the same report last year.
Same report last year: 734K; its normal report is 763K.
See the evidence
This period
1.1M (the 15 May 2024 report)
Normal report (median of 24 earlier)
763K
Typical spread (median absolute deviation)
47K
How far from its usual level
+4.4
Same report last year
734K
History used
1,293 days
the 15 May 2024 report24 earlier reportsnormal: 763K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.0M shares sold short in the 31 May 2022 report, 1.9× the same report last year.
Same report last year: 1.6M; its normal report is 1.9M.
See the evidence
This period
3.0M (the 31 May 2022 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
188K
How far from its usual level
+3.7
Same report last year
1.6M
History used
578 days
the 31 May 2022 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 54 entries; narrow the window or the kind of data to see older ones.
Not listed: 62 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001799448
Ticker
ALGS
Domain
aligos.com
Employer name
Aligos Therapeutics, Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
aligos therapeutics
Name
Aligos Therapeutics, Inc.
Uei
ED19ABDRLV29
DOL H-1B labor condition applications and PERM certifications21 data points13 Jun 2022 to 6 Jul 2026
Federal lobbying disclosures (LDA)1 record, 35 data points24 Jan 2023 to 30 Sep 2026
SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)84 records16 Jan 2020 to 6 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)407 data points31 Dec 2018 to 30 Sep 2026
SEC Form 4 insider transactions5 records, 12 data points20 Oct 2020 to 27 Oct 2023
FINRA short interest (twice monthly)431 data points30 Oct 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3064 data points16 Oct 2020 to 20 Nov 2026
USASpending.gov federal awards1 record, 15 data points18 Sep 2023 to 18 Jun 2025